Multi-ancestry Genome-wide Association Study of Varicose Veins Reveals Polygenic Architecture, Genetic Overlap with Arterial and Venous Disease, and Novel Therapeutic Opportunities

Michael G. Levin, Jennifer E. Huffman, Anurag Verma, Kyle A. Sullivan, Alexis Rodriguez, David Kainer, Michael R. Garvin, Matthew Lane, Hyejung Won, Binglan Li, Yuan Luo, Gail P. Jarvik, Håkon Håkonarson, Elizabeth A. Jasper, Alexander G. Bick, Marylyn D. Ritchie, Daniel Jacobson, Ravi Madduri, Scott M. DamrauermedRxiv 2022 · DOI

TL;DR

Researchers have conducted the largest multi-ancestry genome-wide association study (GWAS) of varicose veins to date, identifying 139 genetic risk loci—a nearly four-fold increase over previous studies. The findings reveal that varicose veins share a surprising genetic foundation with arterial diseases and suggest that height and obesity are not just correlated, but likely causal risk factors.

What Problem Does This Paper Address?

Varicose veins (VV) are far more than a cosmetic concern; they affect nearly 40% of the adult population and can lead to chronic pain, ulcers, and serious conditions like deep vein thrombosis. Despite their prevalence and known heritability, our understanding of the molecular "why" behind VV has been murky.

Previous genetic studies were relatively small and focused almost exclusively on individuals of European ancestry. Furthermore, medical (non-surgical) treatments are severely limited. This paper seeks to bridge these gaps by using massive, diverse datasets to pinpoint the specific genes involved and identify existing drugs that might be repurposed to treat the condition.

Methods

The authors employed a multi-layered "systems biology" approach:

  • Multi-ancestry GWAS Meta-analysis: They combined data across four major ancestral groups to find genetic variants (SNPs) associated with VV.
  • Fine-mapping (MR-MEGA): This statistical technique was used to narrow down broad "risk regions" to specific, likely causal, DNA variants.
  • Mendelian Randomization (MR): Think of this as "nature’s randomized controlled trial." By using genetic variants as proxies for risk factors (like height or protein levels), the researchers could infer whether these factors actually cause VV rather than just being associated with it.
  • Topological Enrichment (Random Walk with Restart): Instead of just looking at a list of genes, they mapped these genes onto a "multiplex network" of 12 different biological data layers (like protein-protein interactions and gene expression). They used an algorithm to see how "connected" GWAS-identified genes were to known biological pathways.

Datasets

The study leveraged a massive sample size of 49,765 cases and over 1.3 million controls. Data was pulled from:

  • The VA Million Veteran Program (MVP): A primary source providing diverse ancestry.
  • UK Biobank (UKB)
  • eMERGE Network
  • FinnGen (Finland)
  • BioBank Japan

Key Insights and Ideas

  • The Arterial-Venous Blur: Traditionally, doctors view venous diseases (like VV) and arterial diseases (like peripheral artery disease) as distinct. This study found significant genetic correlation between them, suggesting shared underlying vascular biology.
  • Causal Anthropometrics: While we knew tall or obese people get more varicose veins, MR analysis suggests these are causal drivers. Increased height and body mass index (BMI) directly increase the risk of developing the disease.
  • The Role of the Extracellular Matrix (ECM): The study highlighted MFAP2, an ECM protein. It appears that disruptions in how the vein wall is built and remodeled are central to the disease's progression.
  • Blood Pressure Paradox: While high systolic blood pressure is a major risk for arterial disease, the study found an inverse genetic correlation with varicose veins, highlighting a unique physiological difference in how veins and arteries respond to pressure.

Key Results

  • 139 Risk Loci: The study identified 139 independent regions of the genome associated with VV, 100+ of which are novel. This represents a 3.8-fold improvement in discovery over previous work.
  • Fine-mapping Success: They were able to narrow down 70 of these loci to a single, high-probability causal variant.
  • Therapeutic Targets: Using MR, they prioritized 69 actionable drug targets. A standout was PDE4C; the study provides genetic evidence that inhibiting phosphodiesterase (a class of drugs already used for other vascular issues) could be a viable non-surgical treatment for VV.
  • Heritability: The researchers estimated the SNP-based heritability of varicose veins to be approximately 15.7%.

Limitations and Future Work

The authors acknowledge several key limitations:

  • Sex Bias: The VA Million Veteran Program cohort is >90% male. Given that varicose veins are more prevalent in women (often linked to pregnancy), future studies need to explore sex-specific genetic architectures.
  • EHR Limitations: The study relied on electronic health record (EHR) codes, which don't always capture the severity or specific clinical subtypes of the disease.
  • MR Assumptions: While Mendelian Randomization is a powerful tool for inferring causality, it assumes that the genetic variants used don't affect the outcome through some other, unknown pathway (pleiotropy).

Future research will likely focus on validating the prioritized drug targets (like PDE4C) in clinical trials and exploring how gene-environment interactions—specifically obesity—alter individual risk.

Summary updated

Abstract

ABSTRACT Background Varicose veins represent a common cause of cardiovascular morbidity, with limited available medical therapies. Although varicose veins are heritable and epidemiologic studies have identified several candidate varicose veins risk factors, the molecular and genetic basis remains uncertain. Here, we analyzed the contribution of common genetic variants to varicose veins using data from the VA Million Veteran Program and other large multi-ancestry biobanks. Among 49,765 individuals with varicose veins and 1,334,301 disease-free controls, we identified 139 risk loci. We identified genetic overlap between varicose veins, other vascular diseases, and dozens of anthropometric factors. Using Mendelian randomization, we prioritized novel therapeutic targets via integration of proteomic and transcriptomic data. Finally, topological enrichment analyses confirmed the biologic roles of endothelial shear flow disruption, inflammation, vascular remodeling, and angiogenesis. These findings may facilitate future efforts to develop non-surgical therapies for varicose veins.
BibTeX
@misc{levin2022multi,
  author = {Michael G. Levin and Jennifer E. Huffman and Anurag Verma and Kyle A. Sullivan and Alexis Rodriguez and David Kainer and Michael R. Garvin and Matthew Lane and Hyejung Won and Binglan Li and Yuan Luo and Gail P. Jarvik and Håkon Håkonarson and Elizabeth A. Jasper and Alexander G. Bick and Marylyn D. Ritchie and Daniel Jacobson and Ravi Madduri and Scott M. Damrauer},
  title = {{Multi-ancestry Genome-wide Association Study of Varicose Veins Reveals Polygenic Architecture, Genetic Overlap with Arterial and Venous Disease, and Novel Therapeutic Opportunities}},
  year = {2022},
  doi = {10.1101/2022.02.22.22271350},
  howpublished = {medRxiv},
}
Figure